Keyphrases
6-cycles
14%
Adjuvant Therapy
14%
Carboplatin-paclitaxel
14%
Complete Response
14%
Completion of Therapy
14%
Concurrent Chemotherapy
14%
Concurrent Radiation
14%
Duration of Response
14%
Fluorescence in Situ Hybridization
14%
Gene Amplification
14%
HER2 Testing
14%
HER2-positive
14%
Her2neu
57%
High Mortality
14%
Immunohistochemistry
14%
Malignancy
14%
Metastatic Disease
28%
Mortality Response
14%
Neoadjuvant Setting
14%
No Evidence of Disease
28%
Palliative Setting
14%
Palliative Treatment
14%
Poor Response
14%
Response to Treatment
14%
Retrospective Review
14%
Salivary Duct Carcinoma
100%
Second-line Chemotherapy
14%
Trastuzumab
100%
Weekly Paclitaxel
14%
Medicine and Dentistry
Adjuvant Therapy
14%
Cancer
14%
Carboplatin
14%
Chemotherapy
14%
Disease
28%
Fluorescence in Situ Hybridization
14%
Gene Amplification
14%
Immunohistochemistry
14%
Metastatic Carcinoma
28%
Paclitaxel
14%
Salivary Duct Carcinoma
100%
Second-Line Chemotherapy
14%
Symptomatic Treatment
14%
Trastuzumab
100%
Nursing and Health Professions
Adjuvant Therapy
14%
Carboplatin
14%
Disease
28%
Fluorescence in Situ Hybridization
14%
Immunohistochemistry
14%
Metastasis
28%
Paclitaxel
14%
Palliative Therapy
14%
Salivary Duct Carcinoma
100%
Trastuzumab
100%
Pharmacology, Toxicology and Pharmaceutical Science
Carboplatin
14%
Chemotherapy
14%
Disease
28%
Metastasis
28%
Paclitaxel
14%
Salivary Duct Carcinoma
100%
Second-Line Chemotherapy
14%
Trastuzumab
100%